Disclaimer

These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2017 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
Our Mission: Become The Global Precision Oncology Partner of Choice

RESEARCH - DISCOVERY -
PARTNERING WITH LEADING RESEARCH INSTITUTIONS TO DRIVE INNOVATION AND DEVELOP NEW INSIGHTS

CLINICAL TRIALS - DEVELOPMENT -
PROVIDING UNPARALLELED EXPERTISE TO BIOPHARMA COMPANIES FOR IMPROVED THERAPEUTIC DEVELOPMENT

PATIENT CARE - DIAGNOSTICS -
DELIVERING GENOMIC INSIGHTS TO PHYSICIANS TO PERSONALIZE TREATMENT & IMPROVE OUTCOMES

INNOVATION & EXECUTION
Company Highlights

1. **Uniquely Positioned Across the Oncology Lifecycle**
   Utilizes unique, proprietary diagnostic tests and integrated AI platform to maximize potential synergies and efficiencies in the oncology care continuum

2. **Large and Growing Market Opportunity**
   Addressing a total market of $22 billion across multiple synergistic end-markets

3. **Respected Name in Hematological and Solid Tumor Testing**
   Offers specialized oncology tests and services, covering the top 10 cancers by prevalence in the US

4. **Contracts with 9 of 10 Top Biopharma Companies, with 108 Current Immuno-Oncology Projects**
   Successfully supported 249 clinical trials with testing, genomic services and biomarker capabilities; of 342 current projects, 108 are I-O projects

5. **Drug Discovery Collaborations with Leading Academic Research Institutions**
   15+ active research collaborations with leading institutions such as the Cleveland Clinic, Columbia University and Memorial Sloan-Kettering Cancer Center

6. **Premier Developer of Proprietary Oncology Tests**
   Developed 21 proprietary, commercially-launched tests targeting cancers such as lung, breast, colon, and prostate cancer

7. **Multiple Near Term Opportunities for Growth**
   Pipeline opportunities include the continued expansion of the recently launched AntigenID, a revolutionary bioinformatics platform, and Liquid::Lung, CGI’s proprietary liquid biopsy test for lung cancer

8. **Robust IP Portfolio**
   Owns 26 US patents and 175 international patents
Targeting the Growing Precision Oncology Market

Global Oncology Costs Expected to Exceed $150 BN by 2021

<table>
<thead>
<tr>
<th>Year</th>
<th>US</th>
<th>EU</th>
<th>Japan</th>
<th>Emerging</th>
<th>Rest of World</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>$30 BN</td>
<td>$50 BN</td>
<td>$20 BN</td>
<td>$20 BN</td>
<td>$20 BN</td>
</tr>
<tr>
<td>2016</td>
<td>$35 BN</td>
<td>$60 BN</td>
<td>$25 BN</td>
<td>$25 BN</td>
<td>$25 BN</td>
</tr>
<tr>
<td>2021</td>
<td>$40 BN</td>
<td>$70 BN</td>
<td>$30 BN</td>
<td>$30 BN</td>
<td>$30 BN</td>
</tr>
</tbody>
</table>

$147- $177 BN

$22 BN Global Addressable Market

- Clínica: $11 BN
- Biopharma: $9 BN
- Discovery: $2 BN

These markets require and share many of the same technologies, tests and similar regulatory oversight.

CGI’s unique business model addresses all 3 synergistic end-markets.

Source: QuintilesIMS, MIDAS, Q4 2016, QuintilesIMS Institute, Mar 2017.
Experienced Leadership Team

John A (Jay) Roberts, MBA
CHIEF EXECUTIVE OFFICER
- 25+ years operational and finance experience
- Previously served as CFO of Clarient, VirMedica, and AdvantEdge

Ralf Brandt, PhD
PRESIDENT, DISCOVERY & EARLY DEVELOPMENT SERVICES
- 25+ years in biochemistry and cell biology
- Co-founder of vivoPharm

John Pappajohn
CHAIRMAN, BOD
- Involved in 100+ start-up companies and served as director of 40+ public companies, many in the bioscience and health-related industries

Michael McCartney, MBA
CHIEF COMMERCIAL OFFICER
- 20+ years in life sciences, diagnostic and lab services
- Former CEO/COO of SciKon Innovation; held positions at BioAgilytix, Roche, Siemens, Abbott

Rob Fannon, MBA, MPH
VICE PRESIDENT, BIOPHARMA SOLUTIONS
- 10+ years in molecular test and panel development
- Served at Roche, where he oversaw biospecimen acquisition

Representative Prior Experience
Well Positioned to Benefit From The Expanding I-O & Immune Therapy Landscape

Immuno-oncology Drugs Have the Potential to Impact up to 60% of All Cancer Patients

Immuno-oncology Drug Sales Expected to Reach $50 BN by 2025

CGI’s Extensive Approach For I-O:

- Immunohistochemistry ("IHC")
  - to detect critical biomarkers such as PD-L1 [FDA approved]

- Immunophenotyping & Flow Cytometry
  - to assess immune response against cancers

- Transcriptome Profiling & Sequencing via NGS
  - to measure expression levels of drug targets

- Antigen & Neoepitope Selection – AntigenID
  - to gauge the effectiveness of I-O therapies & patient response

CGI Offers ALL PD-L1 Companion Diagnostic Tests Available on the Market for Immuno-oncology Therapies

CGI Listed by MERCK as National Reference Lab for KEYTRUDA Expected Sales of $5.8 BN By 2025
CGI’s Current Business Strategy

**Profitability Focus**
- Continue to both aggressively drive revenue growth initiatives, particularly within the Biopharma business unit, and manage the cost structure by streamlining costs across laboratory facilities and consolidating operations.

**Partnership Expansion**
- Leverage specialized, disease-focused genomic and molecular knowledge, insights and portfolio to secure additional collaborations or partnerships with leading biotech and pharmaceutical companies and CROs.

**vivoPharm Synergies**
- Leverage vivoPharm in order: to deepen relationships with existing clients; to expand unique portfolio of Discovery Service offerings in the US and internationally; and to provide integrated service offerings.

**Central Lab and CRO Relationships**
- Leverage clinical and biopharma sales force and relationships with global central laboratories and CROs to expand the existing customer base.

**Innovation**
- Continue focus on translational oncology and drive innovation and cost efficiency in diagnostics by continuing to develop NGS offerings independently and through joint venture with Mayo Clinic and other key opinion leaders and their organizations.

**Value Proposition**
- Improve the quality of clinical data and identify patients for biopharma partners, thereby reducing the time and cost of clinical trials.
Biopharma: Growing Revenue with Impressive Biopharma Customer Base

CONTRACTS WITH

9 OF 10

TOP BIOPHARMA COMPANIES

241

CLINICAL TRIALS SUPPORTED WITH TESTING, GENOMIC SERVICES AND BIOMARKER CAPABILITIES

Biopharma and Total Revenue

= Total Revenue
= Biopharma Revenue

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2.7M</td>
<td>$5.6M</td>
<td>$11.6M</td>
<td>$15.3M</td>
<td>$14.7M</td>
<td></td>
</tr>
<tr>
<td>$4.3M</td>
<td>$6.6M</td>
<td>$10.2M</td>
<td>$18.0M</td>
<td>$27.0M</td>
<td></td>
</tr>
</tbody>
</table>

TOP BIOPHARMA COMPANIES

CONTRACTS WITH

9 OF 10

TOP BIOPHARMA COMPANIES

241

CLINICAL TRIALS SUPPORTED WITH TESTING, GENOMIC SERVICES AND BIOMARKER CAPABILITIES

Representative Customers

- abbvie
- Allergan
- Bristol-Myers Squibb
- Daiichi-Sankyo
- Gilead
- deciphera
- Effector
- Daiichi-Sankyo
- Epizyme
- ICON
- GSK
- GlaxoSmithKline
- H3 Therapeutics
- Janssen
- Karyopharm Therapeutics
- leidos
- Novartis
- AEGIS
- Merck
- Pfizer
- Sanofi
- Roche
- Dako
- Ventana
Revenue & Growth Highlights

3rd Quarter Revenue

- Q3 2015: $4.0M
- Q3 2016: $6.8M
- Q3 2017: $8.0M
- Q3 2018: $5.9M

1st Half Year Revenue

- 1H 2014: $2.9M
- 1H 2015: $8.6M
- 1H 2016: $13.1M
- 1H 2017: $13.6M
- 1H 2018: $14.7M

- 5-Year CAGR: 38%

Full Year Revenue

- 2014: $10.2M
- 2015: $18.0M
- 2016: $27.0M
- 2017: $29.0M

- 4-Year CAGR: 30%
Revenues by Market & Customer Category

Q3 2018 $5.9M

$3.9M BIOPHARMA SERVICES
- Supports 241 clinical trials and studies focused on Solid Tumor and Blood Cancers, including 55 for immuno-oncology indications.

$1.6M CLINICAL SERVICES
- Over 12,000 tests performed in Q3 2018. Comprehensive test portfolio includes immuno-oncology and liquid biopsies.

$0.5M DISCOVERY SERVICES
- Supporting hundreds of clinical trials, driving support for molecular testing and bioinformatics for pre-clinical initiatives and therapeutic discovery.

FY 2017 $29.1M
- 50% 37%
- 13%

1H 2018 $14.7M
- 49% 31%
- 20%
Business Unit Overview: Biopharma Services

CGI offers laboratory and specialized oncology testing services and personalized functional genomic tools and deep learning for biopharma companies engaged in clinical trials.

Select Clinical Trial Services
- Clinical Trial Logistics & Design
- Customized Assay Development
- Next Generation Sequencing
- Exome Sequencing
- DNA & RNA Sequencing
- Cell-free DNA Analysis
- DNA & RNA Microarray
- Anatomic Pathology
- Companion Diagnostics
- Biostatistics & Bioinformatics
- Biorepository & Sample Logistics
- Sanger Sequencing
- Fragment Size Analysis
- DNA & RNA Extraction and Purification

Facilities
- NEW JERSEY: Rutherford
- NORTH CAROLINA: RTP
- CHINA: Shanghai

Biopharma services work performed at headquarters in New Jersey, as well as North Carolina laboratory in Research Triangle Park ("RTP").

Sales Force
Partnerships with central labs and CROs, such as ICON plc and Quest Oncology, to offer clinical trial and companion diagnostic solutions to the global biopharma industry.

8 Member US biopharma and clinical trials sales force.
CGI provides tools and testing methods for companies and researchers seeking to identify new molecular- and biomarker-based indicators for disease

Service Offerings

- Development of Both Xenograft and Syngeneic Animal Models
- Toxicology and Genetic Toxicology Services
- Pharmacology Testing
- Pathology Services
- Validation of Biomarkers for Diseases Including Cancers

vivoPharm specializes in planning and conducting unique, specialized studies to guide drug discovery and development from compound discovery through generation of both in vitro and in vivo testing to support Investigational New Drug ("IND") applications

- Highly scalable platform for early discovery, pre-clinical and pharmacology
- Provides consulting, guidance and preparation of samples and clinical trial design
- 200 INDs supported across 20+ indications with a significant focus on immuno-oncology
- 30+ immuno-oncology studies and trials
- 2 state-of-the-art GLP discovery and early development labs in Pennsylvania and Australia

Preclinical development of biomarker detection methods, response to immuno-oncology directed novel treatments and early prediction of clinical outcome is supported by extended portfolio of orthotopic, xenografts and syngeneic tumor test systems.
Significant Momentum Achieved in Biopharma & Discovery

- **TOTAL ACTIVE PROJECTS**
  - CGI: 191 (Q3 2017), 249 (Q2 2018), 377 (Q3 2018)
  - vivoPharm: 342 (Q3 2017), 93 (Q2 2018), 136 (Q3 2018)

- **ACTIVE I-O PROJECTS**
  - CGI: 52 (Q3 2017), 108 (Q2 2018), 124 (Q3 2018)
  - vivoPharm: 53 (Q3 2017), 61 (Q2 2018), 61 (Q3 2018)

- **BOOK TO BILLING RATIO**
  - CGI: 1.6 (Q3 2017), 3.4 (Q2 2018), 2.4 (Q3 2018)

- **Key Metrics**
  - 2-fold increase YoY in biopharma projects from 191 to 377 projects
  - 10% increase QoQ in biopharma projects
  - 2.4-fold increase YoY from 52 to 124 immuno-oncology projects
  - 15% increase QoQ in immuno-oncology projects
  - Biopharma book to billing ratio of 2.4 on $8.9M of Q3 2018 bookings
  - Near-record quarterly biopharma bookings of $8.9M, up 35% over Q3 2017 bookings of $6.6M
CGI utilizes an expansive range of molecular- and biomarker-based tests and technologies to provide a personalized, comprehensive profile for individual patients to help diagnose, monitor and inform cancer treatment.
Recent Accomplishments & Expected Milestones

Feb 2018
Focused Business Plan – with emphasis on BioPharma and Discovery

April 2018
Sold India business consistent with transformation & business strategy

May 2018
Began consolidation of L.A. facility and relocation

July 2018
Closed on $2.65M convertible note financing

Sept 2018
Completed consolidation of LA; Materially reducing operating costs

2019
Expected to reach cash-flow breakeven
CANCER GENETICS INCORPORATED
A Leader in Precision Oncology

THANK YOU

October 2018

Nasdaq (CGIX)